Biocon Biologics as a leading global biosimilars company serves patients in over 120 countries worldwide, including more than 80 Emerging Markets. Through our high-quality biosimilars, we address unmet patient needs for affordable therapy options in countries across the Asia-Pacific (APAC), Latin America (LATAM), Africa, the Middle East, Turkey (AFMET), and the Commonwealth of Independent States (CIS) regions.
In these Emerging Markets, Biocon Biologics is transforming lives by expanding access to life-saving and life-improving therapies for conditions like diabetes, cancer, and autoimmune diseases with our portfolio of eight commercialized biosimilars. Committed to ensuring no patient is left behind, we focus on accessibility and affordability, providing cost-effective alternatives to expensive biologics and improving patient outcomes while optimizing healthcare system resources.
We address large patient pools in the Emerging Markets, with our affordable insulins portfolio and oncology and immunology products, which are affordable alternatives to expensive Biologics. We maximize patient reach through self-led, partner-driven and Hybrid commercial models tailored to each country’s needs. We have our commercial teams in several Emerging Markets like Malaysia, the Philippines, Thailand, Brazil, Saudi Arabia, Morocco, South Africa, and the UAE—which enable us to serve patients more closely while realizing the full value potential of the Biocon Biologics brand. In many other Emerging Markets, Biocon Biologics partners with leading local pharma companies to deliver biosimilars that make a real difference in patients’ lives.
Over the years, we have significantly expanded our presence, achieving dominant market shares in various countries for our insulins (rh-Insulin, Insulin Glargine) and cancer therapies (Trastuzumab, Bevacizumab, Pegfilgrastim).
We remain committed to enabling equitable access to life saving therapies to patients across the globe with a special focus on Low and Middle Income Countries. (LMICs)
